相关实验视频

Updated: Jan 18, 2026

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

帕特立马布德鲁克斯能诱导免疫性细胞死亡

Sabrina Forveille^1,2, Liwei Zhao^1,2, Allan Sauvat^1,2

¹Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, Université Paris Saclay, Villejuif, France.

|June 3, 2025

概括

帕特立马布德鲁克斯泰干是一种针对HER3的抗体-药物结合体,在癌细胞中触发免疫细胞死亡 (ICD). 这种作用引起免疫反应,导致瘤排斥和在临床前模型中的免疫记忆.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

抗体与药物联合体 (ADC) 是为向癌症治疗而设计的.
帕特立马布德鲁克斯坦向Erb-B2受体氨酸激酶3 (HER3) 的目标.
了解ADCs的精确作用机制对于优化其疗效至关重要.

研究的目的:

为了描述patritumabderuxtecan的作用方式.
研究其对癌细胞活力和免疫细胞死亡 (ICD) 的影响.
为了评估其在体内引起抗瘤免疫力的潜力.

主要方法:

利用人类骨髓瘤细胞进行工程,以表达HER3.
评估细胞活力和卡尔雷蒂库林暴露.
测量HMGB1和ATP释放作为ICD的标记物.
通过有效载荷DXd.d.研究DNA到RNA转录的抑制.
在小鼠模型中评估体内抗瘤免疫力.

主要成果:

帕特里巴deruxtecan降低了癌细胞活力,并诱导了calreticulin的迁移.
无论是ADC还是它的有效载荷DXd都诱导了ICD的关键特征,包括calreticulin暴露,HMGB1和ATP释放.
DXd迅速抑制了DNA-RNA转录,这是ICD的一个预测因素.
用DXd治疗的癌细胞在小鼠中诱导了抗瘤免疫和免疫记忆,导致瘤在重新挑战时被排斥.

结论:

帕特里图马布德鲁克斯泰坎的细胞毒性有效载荷在体外诱导了ICD的特征.
在体内,ADC有效地引起抗瘤免疫和免疫记忆.
这些发现支持了patritumab deruxtecan在癌症治疗中的治疗潜力.

关键词:

抗体药物联合体的抗体.抗癌免疫力抗癌免疫力癌症癌症癌症癌症癌症免疫疗法免疫疗法

更多相关视频

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Selective Cell Elimination from Mixed 3D Culture Using a Near Infrared Photoimmunotherapy Technique

Selective Cell Elimination from Mixed 3D Culture Using a Near Infrared Photoimmunotherapy Technique

Published on: March 14, 2016

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...